Cedric Francois - 25 Apr 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Signature
/s/ David Watson, attorney-in-fact for Cedric Francois
Issuer symbol
APLS
Transactions as of
25 Apr 2022
Net transactions value
-$1,236,304
Form type
4
Filing time
21 Dec 2022, 15:13:17 UTC
Previous filing
14 Feb 2022
Next filing
24 Jan 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Other $0 -12,500 -1.3% $0.000000 943,440 25 Apr 2022 Direct F1
transaction APLS Common Stock Options Exercise $75,294 +28,200 +3% $2.67* 971,640 19 Dec 2022 Direct F2
transaction APLS Common Stock Options Exercise $56,400 +15,000 +1.5% $3.76* 986,640 19 Dec 2022 Direct
transaction APLS Common Stock Options Exercise $99,986 +6,688 +0.68% $14.95 993,328 19 Dec 2022 Direct
transaction APLS Common Stock Sale $194,931 -3,751 -0.38% $51.97 989,577 19 Dec 2022 Direct F2, F3
transaction APLS Common Stock Sale $1,273,052 -24,449 -2.5% $52.07 965,128 19 Dec 2022 Direct F2, F4
holding APLS Common Stock 300,000 25 Apr 2022 The Francois Grossi Trust F5
holding APLS Common Stock 234,411 25 Apr 2022 The Francois-DuBois Educational Trust F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -28,200 -5.9% $0.000000 450,000 19 Dec 2022 Common Stock 28,200 $2.67 Direct F2, F7
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -15,000 -5.5% $0.000000 258,840 19 Dec 2022 Common Stock 15,000 $3.76 Direct F8
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -6,688 -2.4% $0.000000 273,312 19 Dec 2022 Common Stock 6,688 $14.95 Direct F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This represents the cancellation of a PSU awards granted on 01/28/2021 that was originally reported in table I upon grant. The performance metrics were not met.
F2 This is a scheduled exercise & sale from 10b5-1 plan adopted September 13, 2022 .
F3 Sale price within range of $1. Min. $50.695 - Max. $51.680
F4 Sale price within range of $1. Min. $51.695 - Max. $52.400
F5 The securities are held by The Francois Grossi Trust, for which Juliana Grossi, the spouse of the reporting person, serves as trustee. The reporting person disclaims beneficial ownership over the shares held by the Francois Grossi Trust except to the extent of his pecuniary interest therein.
F6 The securities are held by The Francois-DuBois Educational Trust, for which the Fiduciary Trust Company of New England serves as trustee. The reporting person disclaims beneficial ownership over the shares held by The Francois-DuBois Educational Trust except to the extent of his pecuniary interest therein.
F7 This option was granted on December 5, 2013 and fully vested.
F8 This option was granted on February 8, 2016 and fully vested.
F9 This option was granted on February 16, 2018 and will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.